Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus

Interferon (IFN) inhibits hepatitis C virus (HCV) replication through up-regulation of intrahepatic IFN-stimulated gene expression but also through activation of host immune cells. In the present study, we analyzed the immune cell-mediated antiviral effects of IFN-α using HCV-infected mice. Urokinase-type plasminogen activator (uPA)-severe combined immunodeficiency (SCID) mice with transplanted human hepatocytes were infected with genotype 1b HCV and injected with human peripheral blood mononuclear cells (PBMCs). IFN-α treatment following human PBMC transplantation resulted in a significant reduction in serum HCV RNA titers and a higher human CD45-positive mononuclear cell chimerism compared to mice without human PBMC transplantation. In mice with human PBMCs treated with IFN-α, serum concentrations of IFN-γ increased, and natural killer T (NKT) cells, especially type I NKT cells, produced IFN-γ. Mice in which IFN-γ signaling was blocked using antibody or in which transplanted PBMCs were depleted for type I NKT cells showed similar levels of anti-HCV effect compared with mice treated only with IFN-α. These results show that IFN-α stimulates IFN-γ expression in type 1 NKT cells and enhances the inhibition of HCV replication. We propose that type 1 NKT cells might represent a new therapeutic target for chronic hepatitis C patients.

[1]  Christoph Sarrazin,et al.  The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. , 2016, Journal of hepatology.

[2]  S. Ahn,et al.  Emerging Therapies for Hepatitis C , 2014, Gut and liver.

[3]  B. Rehermann,et al.  Immune responses to HCV and other hepatitis viruses. , 2014, Immunity.

[4]  M. Imamura,et al.  A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections. , 2013, Biochemical and biophysical research communications.

[5]  B. Rehermann,et al.  Innate immune responses in hepatitis C virus‐exposed healthcare workers who do not develop acute infection , 2013, Hepatology.

[6]  M. Imamura,et al.  Severe necroinflammatory reaction caused by natural killer cell‐mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse , 2012, Hepatology.

[7]  T. Liang,et al.  Early changes in interferon signaling define natural killer cell response and refractoriness to interferon‐based therapy of hepatitis C patients , 2012, Hepatology.

[8]  T. Liang,et al.  Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. , 2011, Gastroenterology.

[9]  M. Imamura,et al.  Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo , 2011, Hepatology.

[10]  P. Klenerman,et al.  T cell responses in hepatitis C: the good, the bad and the unconventional , 2011, Gut.

[11]  M. Smyth,et al.  Presumed guilty: natural killer T cell defects and human disease , 2011, Nature Reviews Immunology.

[12]  Carlo Ferrari,et al.  Activation of natural killer cells during acute infection with hepatitis C virus. , 2010, Gastroenterology.

[13]  T. Tashiro,et al.  The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. , 2010, International immunology.

[14]  M. Imamura,et al.  Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. , 2009, The Journal of clinical investigation.

[15]  G. Michelone,et al.  Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. , 2009, Gastroenterology.

[16]  N. Tanaka,et al.  Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors , 2008, Hepatology.

[17]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[18]  Deborah Chavez,et al.  Genomic response to interferon‐α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics , 2006, Hepatology.

[19]  M. Imamura,et al.  Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus , 2005, Hepatology.

[20]  J. Hoofnagle,et al.  Mechanism of action of interferon and ribavirin in treatment of hepatitis C , 2005, Nature.

[21]  T. Asahara,et al.  Near completely humanized liver in mice shows human-type metabolic responses to drugs. , 2004, The American journal of pathology.

[22]  L. Kaer,et al.  NKT cells: what's in a name? , 2004, Nature Reviews Immunology.

[23]  M. Massari,et al.  Hepatitis C Virus (HCV) RNA Determination After Two Weeks of Induction Interferon Treatment Is an Accurate Predictor of Nonresponse: Comparison of Two Treatment Schedules , 2001, Digestive Diseases and Sciences.

[24]  T. Asahara,et al.  Intraoperative near-infrared spectroscopy for evaluating hepatic venous outflow in living-donor right lobe liver1 , 2003, Transplantation.

[25]  D. Doherty,et al.  Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection. , 2002, Journal of hepatology.

[26]  G. Trinchieri,et al.  Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells , 2002, The Journal of experimental medicine.

[27]  Giovanni Melioli,et al.  Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells , 2002, The Journal of experimental medicine.

[28]  D. Doherty,et al.  Decrease in hepatic CD 56 1 T cells and V a 24 1 natural killer T cells in chronic hepatitis C viral infection , 2002 .

[29]  M. Smyth,et al.  NKT cells: facts, functions and fallacies. , 2000, Immunology today.

[30]  M. Manns,et al.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C , 2000, Nature Medicine.

[31]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[32]  D. Doherty,et al.  The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. , 1999, Journal of immunology.

[33]  O. Lantz,et al.  An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans , 1994, The Journal of experimental medicine.

[34]  V. Reyes,et al.  INTERFERON α/β SYNTHESIS DURING ACUTE GRAFT‐VERSUS‐HOST DISEASE , 1987 .

[35]  V. Reyes,et al.  Interferon alpha/beta synthesis during acute graft-versus-host disease. , 1987, Transplantation.